INDOL-3-CARBINOL IN THE TREATMENT OF BENIGN BREAST DISORDERS
123 patients with various forms of fibrocystic mastopathy (n=114) and fibroadenoma of mammry gland (n=9) were enrolled into the study. Indol-3-carbinol (indinol, Close corporation «Mirax-Pharma») was administered in the dose of 300—400 mg per day for 3—6 months. Disappearance of complaints to pain w...
Saved in:
Main Authors: | E. T. Zulkarnayeva, R. H. Hakimova, Ye. A. Lapan, I. L. Blagodetelev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2014-09-01
|
Series: | Опухоли женской репродуктивной системы |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/364 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Indole-3-Carbinol Enhances Alternative Activation of Macrophages via AHR Pathway and Glucose Transporter Regulation
by: Delara Omrani, et al.
Published: (2025-05-01) -
Indole-3-carbinol induces apoptosis of chronic myelogenous leukemia cells through suppression of STAT5 and Akt signaling pathways
by: Majid Safa, et al.
Published: (2017-05-01) -
Oxidative carbonylation of dimethylethinyl carbinol in oscillation mode.
by: S. N. Gorodsky, et al.
Published: (2008-06-01) -
Medical pathogenetic correction of benign breast disorders
by: N. I. Rozhkova, et al.
Published: (2014-09-01) -
THE TREATMENT OF DIFFUSE BENIGN BREAST DISEASE AND MASTODYNIA
by: N. I. Rozhkova, et al.
Published: (2016-06-01)